|
Synonyms: IL-22Fc | RG 7880 | RG7880 | UTTR1147A
Compound class:
Antibody
Comment: Efmarodocokin alfa is a recombinant human IL-22-Fc IgG4 fusion protein that acts as an agonist of the heterodimeric Interleukin-22α1/10β receptor which is expressed by epithelial cells. It activates the IL-22 signaling pathway without inducing systemic inflammation or causing immunosuppression. Efmarodocokin alfa was developed for potential to treat infectious or inflammatory diseases [2]. The most advanced investigation of its clinical utility has been of its potential to induce repair of the intestinal epithelial damage that is caused by inflammatory bowel diseases [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Rothenberg ME, Wang Y, Lekkerkerker A, Danilenko DM, Maciuca R, Erickson R, Herman A, Stefanich E, Lu TT. (2019)
Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL-22Fc): A Potential Therapy for Epithelial Injury. Clin Pharmacol Ther, 105 (1): 177-189. [PMID:29952004] |
|
2. Stefanich EG, Rae J, Sukumaran S, Lutman J, Lekkerkerker A, Ouyang W, Wang X, Lee D, Danilenko DM, Diehl L et al.. (2018)
Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases. Biochem Pharmacol, 152: 224-235. [PMID:29608910] |
